Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.
about
Epidemiology and risk factors for invasive candidiasisEvolution and Application of Inteins in Candida species: A ReviewAre the Conventional Commercial Yeast Identification Methods Still Helpful in the Era of New Clinical Microbiology Diagnostics? A Meta-Analysis of Their AccuracyDeclining incidence of candidemia and the shifting epidemiology of Candida resistance in two US metropolitan areas, 2008-2013: results from population-based surveillanceSurveillance of the prevalence, antibiotic susceptibility, and genotypic characterization of invasive candidiasis in a teaching hospital in China between 2006 to 2011.Fungemia in a Spanish hospital: the role of Candida parapsilosis over a 15-year period.Epidemiology and Risk Factors for Echinocandin Nonsusceptible Candida glabrata Bloodstream Infections: Data From a Large Multisite Population-Based Candidemia Surveillance Program, 2008-2014Role of FKS Mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance.Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010)Advances in identification of clinical yeast isolates by use of matrix-assisted laser desorption ionization-time of flight mass spectrometry.Species distribution and susceptibility profile to fluconazole, voriconazole and MXP-4509 of 551 clinical yeast isolates from a Romanian multi-centre study.Quick Detection of FKS1 Mutations Responsible for Clinical Echinocandin Resistance in Candida albicans.Posttreatment Antifungal Resistance among Colonizing Candida Isolates in Candidemia Patients: Results from a Systematic Multicenter Study.Diversity and antifungal susceptibility of Norwegian Candida glabrata clinical isolates.Evaluating Epidemiology and Improving Surveillance of Infections Associated with Health Care, United StatesEmerging Infections Program as Surveillance for Antimicrobial Drug ResistanceMultidrug Transporters and Alterations in Sterol Biosynthesis Contribute to Azole Antifungal Resistance in Candida parapsilosis.Rapid development of Candida krusei echinocandin resistance during caspofungin therapy.Epidemiology and reporting of candidaemia in Belgium: a multi-centre study.Comparison of the Bruker Biotyper and VITEK MS Matrix-Assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry Systems Using a Formic Acid Extraction Method to Identify Common and Uncommon Yeast IsolatesAcquired Multidrug Antifungal Resistance in Candida lusitaniae during Therapy.First description of Candida nivariensis in Brazil: antifungal susceptibility profile and potential virulence attributes.Milbemycins: more than efflux inhibitors for fungal pathogensGain-of-function mutations in PDR1, a regulator of antifungal drug resistance in Candida glabrata, control adherence to host cells.Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of Candida glabrata Bloodstream Infections.Identification and antifungal susceptibility of Candida species isolated from bloodstream infections in Konya, Turkey.Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposureIn Vitro Activities of Six Antifungal Drugs Against Candida glabrata Isolates: An Emerging Pathogen.Distinct roles of Candida albicans drug resistance transcription factors TAC1, MRR1, and UPC2 in virulenceDevelopment of a Luminex-based multiplex assay for detection of mutations conferring resistance to Echinocandins in Candida glabrata.Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011.Notable Increasing Trend in Azole Non-susceptible Candida tropicalis Causing Invasive Candidiasis in China (August 2009 to July 2014): Molecular Epidemiology and Clinical Azole Consumption.Current status of antifungal resistance and its impact on clinical practice.Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis virulence in the non-conventional host Galleria mellonella.Learning the ABC of oral fungal drug resistance.Is Fluconazole or an Echinocandin the Agent of Choice for Candidemia.Medically important fungi respond to azole drugs: an update.The Candida albicans agglutinin-like sequence family of adhesins: functional insights gained from structural analysis.Emerging issues, challenges, and changing epidemiology of fungal disease outbreaks.Epidemiology and molecular mechanisms of antifungal resistance in Candida and Aspergillus.
P2860
Q27024911-56AFCC17-BD8E-4F42-8139-4E46DF672DE0Q28078765-1A7416C2-FE2D-4AD1-AEA3-E18A5DDD7F2BQ28084765-4AB8D942-2A83-454B-B2EC-C6F083F6D7DBQ28545137-20F4B98F-BEAF-4399-A2EA-2E31AFE51D16Q30658189-3B8FD6DD-A0F2-4C4D-903B-5116E19AB035Q30808061-D694C9BF-A43F-43A1-9648-656CDBDD4592Q31032549-7EC2F1F2-5514-440B-A523-E13D7A06B4CAQ34058099-BE7DE747-7367-449E-B184-1BF1AB180A0DQ34100598-A3F94761-3B19-41A9-8545-316043C5E388Q34593760-F45C270F-9F07-4701-B84E-D925F60FD49AQ35254046-F6861BC0-20D2-457F-B100-63CC8DCFFBB0Q35757564-0706D123-5E0D-4ED8-A057-F69089EAE8B9Q35880078-037BE07E-3613-45C8-8182-1BF1851B1AFEQ35918893-60C7A755-16EE-4BF8-AD83-E06F1D79200EQ35997443-4CFE3BE1-B4E2-43FE-BEC3-C72DC23EA147Q35997516-2CE02D9D-38BF-48BD-B203-EEED61E31A32Q36076001-1413A8DC-C10F-47C4-88E5-9F932A1156C8Q36158489-85126A76-D0F1-4D11-94BD-5D7D5F742E58Q36196229-D29A1957-3B49-4B05-B047-C56357FF65A5Q36287169-476C3B7B-B78C-4693-82FA-D112CE174C4FQ36290663-EF5A20A7-95C5-475C-83B6-C87900BD7A16Q36503873-CA9E8C68-1474-479D-8DDC-96126D7C052FQ36558410-15269EE5-CFF4-4225-8403-4A7A70F89379Q36827007-EAEACFA6-ED96-4BF0-BC65-F23F7C03ABA1Q36933437-8759E1B1-3878-449F-8407-2EAF54116EFCQ36954989-684A9A16-3161-44A0-B2FB-63A0CFFE4488Q37036603-B84DD954-D78B-4983-AC15-7E13EE091A15Q37160845-68E2E351-46F7-4567-96A2-A22068B0D52AQ37545098-E05E6E50-E1A6-4FDE-8EFC-3CA60E1B6472Q37643499-F6782E72-ED0C-4269-853A-7792FA5832FCQ37643602-6DAEE5CB-D7B5-4C72-B99F-38362A7544CCQ37714473-BC825281-E63F-40B6-9712-8ABB3F54CA6AQ38205859-6909AD27-83BD-45F6-A2C5-4E1C19CE9151Q38297389-7FF410CC-90C5-415D-937A-FFEF67981977Q38515541-31CD3C03-6ACC-47B3-8672-D89B5EDEABBFQ38535647-ABF0AFC8-0859-475A-A7C1-5D24F7483364Q38559208-84D69E24-D1CC-4A5F-9FF9-8776DD2CE5F5Q38599618-2A7DEC9B-CE83-4D22-8C24-63DB338F9C1FQ38647201-880EDA6D-62EE-408F-B7FE-46B97AC09E95Q38711698-2B03D235-3499-4431-868B-DA81C901142F
P2860
Species identification and antifungal susceptibility testing of Candida bloodstream isolates from population-based surveillance studies in two U.S. cities from 2008 to 2011.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Species identification and ant ...... U.S. cities from 2008 to 2011.
@ast
Species identification and ant ...... U.S. cities from 2008 to 2011.
@en
Species identification and ant ...... U.S. cities from 2008 to 2011.
@nl
type
label
Species identification and ant ...... U.S. cities from 2008 to 2011.
@ast
Species identification and ant ...... U.S. cities from 2008 to 2011.
@en
Species identification and ant ...... U.S. cities from 2008 to 2011.
@nl
prefLabel
Species identification and ant ...... U.S. cities from 2008 to 2011.
@ast
Species identification and ant ...... U.S. cities from 2008 to 2011.
@en
Species identification and ant ...... U.S. cities from 2008 to 2011.
@nl
P2093
P2860
P356
P1476
Species identification and ant ...... U.S. cities from 2008 to 2011.
@en
P2093
Angela A Cleveland
Benjamin J Park
Betsy Stein
Carol B Bolden
Lee H Harrison
Monica M Farley
Naureen Iqbal
Rosemary Hollick
Tom Chiller
Wendy Baughman
P2860
P304
P356
10.1128/JCM.01283-12
P407
P577
2012-08-08T00:00:00Z